Dyne Therapeutics Faces Investor Concerns

Dyne Therapeutics shares are trading lower after investors expressed concern over the risks and uncertainties surrounding the clinical and regulatory processes for DYNE-101, despite a recent FDA Breakthrough Therapy Designation announcement.